CytoMed Therapeutics Ltd (GDTC) — Titan Protect Analysis

GDTC

CytoMed Therapeutics Ltd

Healthcare · ·

$1.29

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$13M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.44

Based on estimated future earnings — lower means cheaper

Rev Growth

+46.9%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-50.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About CytoMed Therapeutics Ltd

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a

https://w2.cytomed.sg

Country: Singapore Employees: 42 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.148

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0634

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.299

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-23.7%

Historical annualised return based on price data

Max Drawdown

-79.3%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.17

Very low correlation to market moves

52W High

$3.68

65% below the year high

52W Low

$0.68

90% above the year low

Avg Volume

14,036

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

7.04

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

89.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-535.3%

Profit from core operations before interest and tax

Free Cash Flow

$-2,715,337

Negative — the business is spending more than it generates

Revenue (TTM)

$860,848

Total revenue over the last 12 months

Net Income

$-3,980,457

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go